

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Effectiveness of ginseng compared with gentamicin in the improvement of symptoms in patients with brucellosis

Protocol summary

Summary

In a single blind randomized clinical trial all patients referred to outpatient clinics of Valiasr hospital and Emamreza with clinical symptoms and signs of brucellosis according to inclusion and exclusion criteria enrolled to study. Patients eligible for the study after obtaining informed consent were allocated randomly to one of three intervention groups: (A) 55 patients treated with doxycycline (Manufacture of Razak pharmaceutical Company) 200 mg (6 weeks), Rifampin (Manufacture of Alhavy pharmaceutical Company) 600 mg (6 weeks) and Gentamicin (Manufacture of Caspian pharmaceutical Company) 5 mg/kg per day (1 week) B: 55 patients treated with doxycycline 200 mg daily (6 weeks), rifampin 600 mg daily (6 weeks) plus ginseng (Manufacture of Goldaru pharmaceutical Company) 500 mg once daily (1 week) c: 55 patients were treated with doxycycline 200 mg daily (6 weeks) and rifampin 600 mg daily (6 weeks) are given. The patient's clinical response or treatment failure for 6 weeks and for relapse to 6 months after completion of treatment are evaluated.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201412219855N8**

Registration date: **2015-01-10, 1393/10/20**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2015-01-10, 1393/10/20

Registrant information

Name

Aiasghar Farazi

Name of organization / entity

Arak University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 86 1278 6526

Email address

dr.farazi@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Arak University of Medical Sciences

Expected recruitment start date

2014-10-01, 1393/07/09

Expected recruitment end date

2015-06-01, 1394/03/11

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effectiveness of ginseng compared with gentamicin in the improvement of symptoms in patients with brucellosis

Public title

The effect of ginseng in the treatment of brucellosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: age over 15 years; Wright titer at least 1/160 and 2ME 1/40; informed consent to participate in the study Exclusion criteria: history of brucellosis in the past 2 years; history of chronic brucellosis; pregnant women; having innate or acquired immunodeficiency; history of allergy to ginseng; local forms of brucellosis infection such as endocarditis, spondylitis, etc.; patients

with advanced or chronic disease of heart, lung, liver and kidney

Age

From **15 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **165**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Arak University of Medical Sciences

Street address

Sardasht, Vice Chancellor for Research

City

Arak

Postal code

Approval date

2014-09-29, 1393/07/07

Ethics committee reference number

93-168-4

Health conditions studied

1

Description of health condition studied

Brucellosis

ICD-10 code

A23

ICD-10 code description

Brucellosis

Primary outcomes

1

Description

Disappearance of fever

Timepoint

Days of 0, 3, 5, 7, 14, 21

Method of measurement

With thermometer

2

Description

Resolve of arthralgia

Timepoint

Days of 0, 3, 5, 7, 14, 21

Method of measurement

Questionnaire

3

Description

Constitutional symptoms

Timepoint

Days of 0, 3, 5, 7, 14, 21

Method of measurement

Questionnaire

4

Description

Decrease of CRP

Timepoint

Days of 0,7, 14, 21, 28, 42

Method of measurement

Latex agglutination test

Secondary outcomes

1

Description

Treatment Failure

Timepoint

End of 6 weeks treatment

Method of measurement

No improvement in clinical symptoms and laboratory tests

2

Description

Relapse

Timepoint

Months of 3, 4, 5, 6, 7, 8

Method of measurement

ecurrence of clinical symptoms and laboratory tests

Intervention groups

1

Description

Intervention group 1: doxycycline 200 mg capsules daily (6 weeks) plus rifampin 600 mg capsules daily (6 weeks) plus Ginseng capsules 500 mg daily (1 week)

Category

Treatment - Drugs

2**Description**

Intervention group 2 capsules doxycycline 200 mg (6 weeks) plus rifampin 600 mg once daily (6 weeks) plus gentamicin 5 mg/kg per day (1 week)

Category

Treatment - Drugs

3**Description**

Controls: doxycycline 200 mg capsules daily (6 weeks) plus rifampin 600 mg capsules daily (6 weeks)

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Valiasr hospital

Full name of responsible person**Street address****City**

Arak

2**Recruitment center****Name of recruitment center**

Emamreza Clinic

Full name of responsible person

Aliasghar Farazi

Street address

Department of Infectious Disease, School

City

Arak

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Arak University of Medical Sciences

Full name of responsible person

Dr Ghazavi

Street address

Sardasht, Vice Chancellor for Research

City

Arak

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Arak University of Medical Sciences

Full name of responsible person

Dr Aliasghar Farazi

Position

Associate professor of Infectious Diseases

Other areas of specialty/work**Street address**

department of Infectious Diseases, Valiasr hospital

City

Arak

Postal code

009886341411

Phone

+98 86341411

Fax**Email**

farazialiasghar@yahoo.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Arak University of Medical Sciences

Full name of responsible person

Dr Aliasghar Farazi

Position

Associate professor

Other areas of specialty/work**Street address**

Department of Infectious Disease, Valiasr hospital

City

Arak

Postal code

3813665685

Phone

+98 86341411

Fax**Email**

farazialiasghar@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr Aliasghar Farazi

Position

Associate professor

Other areas of specialty/work**Street address**

Department of Infectious Disease, School of Medicine,
Arak University of Medical Sciences, Arak/Iran

City

Arak

Postal code

3813665685

Phone

00

Fax**Email**

farazialiasghar@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty